|
| |
|
| Pharma Leaders is a bi-monthly publication from Integrral Media Pvt Ltd.. It is the leading pharma title in print and digital versions serving the information needs of key executives from the world’s leading pharmaceutical companies. Pharma Leaderscovers important issues and trends shaping the future of the pharma industry across Asia and rest of the world. Pharma Leaders offers Dedicated, reliable and accurate coverage of the industry’s progress and Incisive analysis to help its readers make informed decisions to stay ahead of the competition.The magazine provides cutting-edge and futuristic content on the pharma industry. The issues are broadly categorized into various sections: |
| • |
Strategy |
| • |
Insight |
| • |
Clinical Trials |
| • |
Drug Discovery |
| • |
Cover Feature Expert Talk |
|
| The one-stop pharma destination www.integrralmedia.com features complete content from the Pharma Leadersvmagazine. Also find the latest pharma news, press releases, pharma industry reports, interviews, trends and pharma events updated on a daily basis.The magazine is supplemented by the monthly e-Newsletter: Pharma Leadersetalks. |
The readership
The magazine’s readership includes the top C-level executives, senior industry executives, and key decision makers from the pharma industry in charge of spending. With a special focus on Asia, Pharma Leaders reaches out to the key industry leaders across Asia, Europe and the Americas.
The Voice
Pharma Leaders provides a unique opportunity to bring your products and services to the attention of key budget holders within the largest pharmaceutical organisations around the world. The publication is made available only to a select group of decision makers who represent a spending power of US$ 350 billion. That money is more and more likely to be heading towards Asia and Europe, and you should make sure you get your share.
The Opportunity
There is a huge market in Europe for Asian products and vice versa. Getting your message across to the major players in these markets is very difficult, unless you have Pharma Leaders and its resources working for you in a consistent manner. Top pharma companies across the world receive Pharma Leaders that has articles and insights contributed by leading industry experts. The readers of Pharma Leadersappreciate the publication because they recognise the value of its independent reporting and the quality of its content. It clearly makes Pharma Leaders a powerful prospect for advertisers.
Published Bi-Monthly with a circulation of circulation of 5,000 copies, Pharma Leaders is distributed across Asia Pacific, the Middle East, Europe and USA. This includes readers who receive the print copies and another 75,000 readers who receive e-book copies. This translates into an estimated readership base of 125,000
The Target Market
Our readers represent the most important organisations in the global pharmaceutical market, and they should be your target market, because your competitors are already targeting them.
Pharma Leaders provides customised advertisement solutions through high quality advertisements placed along side relevent content to receive immediate attention from your target market.
Pharma Leaders, with its total commitment to building exceptional circulation lists, can deliver your message to the right people. Our relationship officers can help you in your marketing plan with highly targeted advertising, aimed directly at the people who hold the purse strings. |
| 1. Circulation: |
A meticulously crafted circulation database of companies that matter to you – A market place custom-built to your needs. |
| 2. Readership: |
Readers are carefully chosen top executives. A judicious blend of purchase decision makers and specifiers - the individuals who matter most to your company. |
| 3. Valuable Content: |
Insights and incisive analysis of industry dynamics and emerging trends in technologies including drug discovery, manufacturing etc., written by the leading experts. |
| 4. Online Presence: |
Listing on the search engine optimised website - Print advert doubling-up as online vehicle. |
|
| |
Pharma Leadersis read by pharma professionals and executives. Therefore, we expect the focus of the articles to be relevant for them. The following guidelines aim to help you write the article(s) to meet our selection criteria.
Key Selection Criterion for Articles
We expect the article to be informative and relevant to the industry and focus on contemporary / futuristic topics. They should be written to deliver learning value to offer new insights to our readers.
|
| Writing Style Suggestions |
| • |
Please note that our in-house style is based on British English |
| • |
We recommend the use of active voice and third person narrative. It will be of help if you can avoid the use of first- and second-person pronouns (I, we, you) |
| • |
Provide short titles for the article and subheads |
| • |
Use simple and uncomplicated language as far as possible |
| • |
Please ensure that clarity is maintained throughout the article. Avoid sentences that are ambiguous or circumlocutory |
| • |
To make the article easy to comprehend, see that all the supplementary information related to the article is provided in user-friendly formats (e.g. Tables, figures, charts etc.) |
| • |
To make the article more interesting and easy to read, important or auxiliary information could be placed separately in sidebars or boxes |
| • |
We do not publish references in the print version. Hence, we advise you to minimise the number of in-text references in the article. However, we do publish references in the magazine’s online version (HTML) |
| • |
Avoid clichés and jargon to the extent possible. Please provide explanations and definitions for the technical terms used to ensure clarity |
|
| Dos and Don’ts
|
| .• |
Article(s) could focus on innovative / cutting-edge technologies and also experiences of the industry’s leading organisations in areas such as best practices etc. |
| • |
The articles that differentiate themselves by offering new insights or share experiences with a larger audience will be given priority. To provide learning value to our readership, articles based on the original research, innovation and/or any new aspect of the industry will be preferred |
| • |
Provide short titles for the article and subheads |
| • |
Articles should be free from copyright infringements and plagiarism. Authors will need to acknowledge all the relevant sources on which their article is based |
| • |
Please provide proper acknowledgements for data, images and tables taken from other relevant sources with permissions wherever applicable |
| • |
All articles undergo a multi-stage review process during which, the author(s) will be informed whether the article has been accepted, rejected or needs revision. The editorial team could suggest improvements to the article on a case-by-case basis |
| • |
The articles written to promote the products or services of the author’s company (unless they represent a breakthrough / innovation in the industry) are considered for publication as advertorials and attract relevant tariff |
|
| Guidelines to Authors |
| .• |
Papers are accepted for publication on the clear understanding |
| |
| A. |
That they have neither been published nor being considered for publication elsewhere. All the authors should sign a certificate to this effect in respect of each article sent for publication. Covering letter should indicate the names, qualification and full address of all the authors. |
| B. |
That the research work has been carried out with the approval of the Institutional Ethics committee and as per the laws in force at the time of carrying out the work and at the time of sending the paper for publication in the country in which the research work was carried out. A certificate to this effect should be signed by all the authors. Authors should get written permission from concerned authorities for publication of articles on emerging and exotic diseases. |
| C. |
All the authors are jointly and severally responsible to the various authorities for the contents of the articles. Neither the Editor nor publisher hold themselves responsible in any manner whatsoever to the contents of the article and the views and interpretation expressed by the author in the article. |
|
| • |
Authors should clearly indicate whether the article is a new or revised or copy of the article already sent. The letter should also furnish complete postal address and e-mail id. of the corresponding author. Article should be typed in A4 size paper in double space, following the format of the Pharma Leaders. Two copies should be sent to the Editor, Pharma Leaders. |
| • |
The decision of the Editor shall be final in all matters pertaining to publication of papers. Editor has the right to do editorial revision of accepted paper with reference to the number of pages, tables and figures before publication if considered necessary. No reason shall be given for non-acceptance of the article. The copyright shall rest with the journal and no part of any paper can be reproduced without the specific permission of the Editor. |
| • |
Receipt of the articles will be acknowledged with the registration number. The author should return the comments of the referees and original article along with two copies of revised articles. When articles are accepted for publication, acceptance letter would be sent from the editorial team. |
| • |
Pharma Leaders Format Title Authors. Place of work (full address with pin code) |
| |
| General Article : |
Brief Introduction (without heading), Materials and Methods, Results and Discussion , Summary, Acknowledgement (Optional) and References. (Not to exceed 6 pages) |
| Clinical Article: |
Brief introduction (without heading), Case history and Observations, Treatment and Discussion, Summary, Acknowledgement(Optional) References. (Not to exceed 4 pages) |
| Short Communication: |
Brief introduction (without heading), Materials and methods, Results and Discussion, Acknowledgment (Optional) References. (Not to exceed 3 pages) |
|
| • |
The page limit is inclusive of tables and references. |
| • |
Citing References.:
In the text, references should be cited by the names of the authors followed by the year of publication in parenthesis. If more than two authors are there, the name of the first author followed by et al. should be used. If within the same section of the article, the reference is repeated, instead of the year loc.cit. should be used within the parenthesis. List of References furnished at the end of the article, should be arranged alphabetically. The author’s name should be followed by the initials and before the last author ‘and’ should be used. The year of publication should be cited with parenthesis. The journal name with approved abbreviation should be in italics, the volume number should be in bold letter and the starting page number should be given after a colon and followed by a full stop. |
|
| |
| TOP |
The Indian Pharmaceutical industry has become the third largest in world in terms of volume and ranks 14th in terms of value at over Rs one lakh crore, the Economic Survey tabled in view of Union Budget 2010 in Parliament said. The Indian pharmaceutical industry has grown from a humble Rs 1,500 crore turnover in 1980 to approximately Rs 1,00,611 crore in 2009-10," the pre-Budget survey said. The growth of the Indian pharmaceutical industry has been fuelled by exports, which increased 25 per cent in 2008-09. "Exports of pharmaceuticals have consistently outstripped imports," The survey said. India exports drug, intermediaries, active pharmaceutical ingredients (APO), finished dosage formulations, bio-pharmaceuticals and clinical services. The top five destinations for such exports are the USA, Germany, Russia, UK and China.The Economic Survey for 2009-10 has indicated that the economy has recovered from the global economic slowdown and expects the GDP growth to bounce to 8.5% in FY 2011 from 7.2% in FY 2010 and further increase high growth path of 9% in FY 2012. The Survey says that the recovery is broad based and responded well to the policy measures undertaken in the wake of global financial crisis. The Survey notices several factors that augur well for the Indian economy such as pick up in merchandise exports, capital flows and non-bank food credit.
Further, the gross domestic savings as a percentage of GDP stands at 32.5% in 2008-09 while the gross domestic capital formation stands at 34.9%. This follows the revival in investment and private consumption demand impressive growth in exports in November and December and remarkable turn around in Core infrastructure sector. As regards Agriculture, some of the decline in Khariff acreage may have been made up by the increased acreage in the Rabi season. As per the available estimates, wheat, pulses and groundnut have seen an increase in acreage as compared to last year. Economic Survey argued that in services sector, liberalizing FDI in some of the services could create a more conducive environment for trade. Along with systematic marketing of services, collection and dissemination of market information by setting up a portal for services and streamlining the services data system could help the services sector in making further strides. |
| Commends Indian Pharma sector |
| The Indian pharmaceutical industry has grown from a humble Rs 1,500 crore turnover in 1980 to approximately Rs 1,00,611 crore in 2009-10 (September 2009). The country now ranks third in terms of volume of production (10 per cent of global share) and 14th by value. The Indian pharma industry's growth has been fuelled by exports, which registered a growth of 25 per cent in 2008-09. Exports of pharmaceuticals have consistently outstripped imports. India currently exports drug intermediates, active pharmaceutical ingredients (APIs), finished dosage formulations, bio-pharmaceuticals and clinical services. The top five destinations of Indian pharmaceutical products are the USA, Germany, Russia, the UK and China. The domestic pharma sector has also expanded in recent years. |
| Outlook |
The Economic Survey projected rosy picture of the India's growth potential when it said' "Given the steadily improving fundamentals of the economy, the Survey says, if there are improvements in infrastructure, both urban and rural, and reform in governance and administration, it is possible for India to move into double-digit growth and even become the fastest growing economy in the world within next four years." It has also insisted that India could lead from the front by taking bold steps toward reforms as it did in 1991 on the back of the balance-of-payments crisis.
While lauding the all round growth, the survey underscored the need to step up productivity of agriculture and systematic marketing of services, collection and dissemination of market information by setting up a portal for services and streamlining the services data system could help the services sector in making further strides. As regards manufacturing sector, the survey indicated that the ongoing industrial recovery is observed to be broad-based, but it should also be noted that some of the sectors that failed to revive in the current year, like food products, paper products, leather products, jute and cotton textiles and metal products (to an extent), are labour intensive.
Survey seeks to take various initiatives to improve the global competitiveness of the Indian merchandise trade. Reforms suggested for merchandise sector include furthering tariff reforms by lowering the peak duties; weeding out unnecessary customs duty exemptions and streamlining export promotion schemes to reduce duty foregone; further reduction in excise duties to make exports and industry competitive; giving special attention to export infrastructure; fine tuning the trade strategy by targeting exports of dynamic products to developed markets and employment-intensive non-dynamic products to developing country markets; and continuing with our pro-active role in multilateral trade negotiations while taking care of livelihood concerns and the needs of the domestic sector.
Despite all these, the survey has batted alongside Thirteenth Finance Commission recommendation that the combined fiscal deficit of state and centre should come down from 82% in FY 2009-10 (budgeted) to 68% by 2014-15, inclusive of 45% at the Centre and 23% of all the states combined. Whether the government is keen on achieving this, and what will be its roadmap to achieve the same has become critical.
India represents one of the most rapidly emerging healthcare products and services market in the world, with the worth of around US$ 45.8 Billion in 2009. Moreover, the industry has successfully been able to survive amid global financial turmoil owing to prevalence of chronic as well as communicable diseases, among which the most recent is Swine Flu.
According to our newly updated research report “Indian Healthcare - New Avenues for Growth”, the potentials of the Indian healthcare industry are immense and it is expected to rise exponentially owing to increasing per capita healthcare spending and deliberate investments in this sector by the private players. It is expected that this market will grow at a CAGR of around 21% during 2010-2013. The growth of the healthcare market will mainly be driven by factors such as changing demographics profile, epidemiological transitions and increasing health insurance penetration. Our report discusses about all such key drivers that are stimulating growth in the healthcare market.India represents the second most populated country in the world. Our research finds that with a rapidly expanding economy and increasing urbanization, prevalence of a number of chronic diseases, such as cardiovascular, diabetes, arthritis and cancer, will increase rapidly in India. In addition to this, our report also explores that sectors such as medical tourism market and pharma outsourcing market will grow at a CAGR of around 31% and 34% respectively during 2010-2013. So, the country is well-poised to become a source of opportunities for players operating in these segments.
“Indian Healthcare - New Avenues for Growth” contains unique industry research and provides a detailed and objective analysis on the Indian healthcare market. It acquaints clients with statistical and analytical overview of the Indian healthcare market coupled with past, present and future forecast till 2013 on the entire composition and functioning of the Indian healthcare sector. Forecast in this research has been done judiciously, considering the possible post-recession impacts on the industry. It also studies a number of related sectors such as hospital services, pharmaceuticals, medical devices, outsourcing services, medical tourism, infrastructure, medical textiles and path labs. |
| Top |
|
|
|
